Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Procella Therapeutics AB
AB
Active
Org 5590364609
Tullinge
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2015 · 10 years old
20-49 employees
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Procella Therapeutics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
43M
86M
129M
173M
34M
2020
38M
2021
108M
2022
150M
2023
115M
2024
EBITDA
SEK millions
16M
8M
-1M
-9M
-18M
-14M
2020
-8M
+43%
2021
11M
+238%
2022
13M
+18%
2023
-5M
-138%
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
33 573
37 818
107 898
149 623
115 029
Staff expenses
—
—
—
—
−40 453
EBITDA
−14 468
−8 077
11 166
13 186
−4 713
Depreciation & amort.
−5 087
−7 342
−8 777
−15 248
−15 684
EBIT
−19 555
−15 419
2 389
−2 062
−20 397
Net financials
—
−2
3 266
160
4 647
Profit before tax
−19 554
−15 421
12 070
−653
−18 335
Tax
−0
−0
−0
−0
—
Net profit
−19 554
−15 421
12 070
−653
−18 335
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
97 565
301 606
206 249
202 060
97 458
Equity
742
3 622
15 692
34 175
26 168
Long-term debt
0
0
0
0
—
Short-term debt
96 823
297 984
190 557
167 885
71 289
Total debt
96 823
297 984
190 557
167 885
71 289
Financial ratios
5-year trend
EBITDA-margin
-4.1%
This company
15.8%
Market median
-126% vs market
2020
2024
Soliditetsgrad
26.9%
This company
38.2%
Market median
-30% vs market
2020
2024
Egenkapitalforrentning
-70.1%
This company
18.4%
Market median
-481% vs market
2020
2024
Nettoresultatgrad
-15.9%
This company
8.1%
Market median
-296% vs market
2020
2024
Aktivomsætning
1.18×
This company
1.12×
Market median
+5% vs market
2020
2024
Gæld/egenkapital
2.72×
This company
0.62×
Market median
-339% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Procella Therapeutics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
